Ubenimex - Eiger Biopharmaceuticals/Nippon Kayaku
Alternative Names: 1580RB; Bestatin; NK 421; UbestatinLatest Information Update: 09 Feb 2023
At a glance
- Originator Institute of Microbial Chemistry
- Developer Eiger BioPharmaceuticals, Inc.; Nippon Kayaku
- Class Antineoplastics; Branched-chain amino acids; Dipeptides; Essential amino acids; Small molecules
- Mechanism of Action Aminopeptidase B inhibitors; Aminopeptidase inhibitors; Immunostimulants; Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute nonlymphocytic leukaemia
- Discontinued HIV infections; Inflammation; Lymphoedema; Pulmonary arterial hypertension
Most Recent Events
- 09 Feb 2023 Discontinued - Preclinical for Inflammation in USA (PO)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 28 Feb 2019 Eiger BioPharmaceuticals completes the ULTRA trial for Lymphoedema in Australia and USA (NCT02700529)